To test whether knockdown of ZNF251 in breast cancer cells induces resistance to additional PARPis, we tested the resistance of ZNF251KD MDA-MB-436 clones to several potent PARPis, including niraparib (PARP1/2 inhibitor), veliparib (PARP1/2 inhibitor), NMS-P118 (selective PARP1 inhibitor), and stenoparib (PARP1/2 and PARP5a/5b inhibitor). This evidence concerns the gene PARP1 and breast carcinoma.